Business Context and Reporting Period
This Form 8-K Current Report was filed by Milestone Pharmaceuticals Inc. on March 27, 2023 (signed March 31, 2023). The Company, incorporated in Québec and trading on Nasdaq under the symbol "MIST," is an emerging growth company focused on developing etripamil. The filing primarily discloses the execution of significant financing agreements to support its operations and product development.
Key Financial Metrics and Obligations
The filing details two major financial transactions executed on March 27, 2023, with closing occurring on March 29, 2023:
- Royalty Purchase Agreement: The Company agreed to sell a tiered quarterly royalty interest on U.S. net product sales of etripamil (contingent on FDA approval) for a purchase price of $75.0 million.
- Convertible Senior Notes: The Company issued and sold $50 million principal amount of 6.0% Convertible Senior Notes due 2029 (the "2029 Convertible Notes").
- Note Terms: Interest is payable quarterly in cash or, at the Company's option, in kind (PIK) for the first three years. The notes mature on March 31, 2029.
- Conversion Terms: Each $1,000 of principal is convertible into 191.0548 shares of common stock, representing an initial conversion price of approximately $5.23 per share.
- Security: The notes are senior secured obligations guaranteed by the Company's wholly owned subsidiary, Milestone Pharmaceuticals USA, Inc., and secured by substantially all assets of the Company and the subsidiary.
Note: This filing does not provide specific revenue, profit, cash flow, or liquidity metrics for the reporting period.
Material Changes and Transaction Details
The primary material change is the creation of direct financial obligations and the sale of royalty rights:
- Debt Incurrence: The Company incurred $50 million in senior secured debt with a 6.0% interest rate.
- Asset Sale: The Company monetized future royalty streams for $75.0 million, subject to FDA approval of etripamil.
- Covenants: Both agreements include customary negative covenants, including limitations on additional indebtedness, liens, disposition of royalty interests, and mergers. The Note Purchase Agreement also includes events of default related to payment compliance, bankruptcy, and specific clinical trial failures.
- Redemption: The 2029 Convertible Notes are redeemable by the Company on or after March 27, 2027, subject to specified conditions, at 100% of the principal amount plus accrued interest.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The Company provided an updated corporate presentation on March 31, 2023, available via its website, which may contain forward-looking information regarding its pipeline and strategy. The financing is intended to support the Company's operations and the development of etripamil.
Risks and Contingencies:
- Regulatory Risk: The $75.0 million royalty purchase is contingent upon FDA approval of etripamil.
- Default Risk: The Note Purchase Agreement lists clinical trial failures as a potential event of default.
- Liquidity and Covenants: The agreements impose restrictions on the incurrence of additional indebtedness and the disposition of assets.
- Unregistered Securities: The notes were sold in a private placement to accredited investors under Section 4(a)(2) and Rule 506 exemptions and are not registered under the Securities Act.
Investor Verification Checklist
- Verify the status of the FDA approval process for etripamil, as the $75.0 million royalty payment is contingent upon this event.
- Review the full text of the Royalty Purchase Agreement (Exhibit 10.1) and Note Purchase Agreement (Exhibit 10.2) for specific covenants and default triggers.
- Assess the impact of the 6.0% interest rate and potential PIK (payment-in-kind) elections on future cash flow and dilution.
- Monitor the Company's website "Investors & Media" section for the March 31, 2023 corporate presentation and future Regulation FD disclosures.
- Confirm the Company's ability to meet the negative covenants regarding additional indebtedness and asset dispositions.